Dr. Rosenstock received his MD from the University of Costa Rica School of Medicine and completed Fellowships in Endocrinology and Diabetes at the Royal Postgraduate Medical School, Hammersmith Hospital, London, UK, and at the University of Texas Southwestern Medical Center. He is Board Certified in Internal Medicine, and Endocrinology and Metabolism.

He is a member of numerous professional societies and is very active with the American Diabetes Association. He is fluent in both English and Spanish.

His clinical and research activities have focused on exploring novel agents and therapeutic strategies to improve glycemic control, particularly early insulin intervention with combination strategies in Type 2 Diabetes.

Over the last 30 years, he has participated in hundreds of clinical trials and has had an active role in the development of new oral agents and insulin preparations acting often as a lead clinical investigator and scientific advisor. He is recognized as a key opinion leader (KOL) in the field of Diabetes and a national and international authority in designing and participating in clinical research trials on novel Diabetes drugs.

Dr Rosenstock has been the author or co-author of more than 450 publications, including peer-reviewed manuscripts and numerous abstracts. He has also contributed to several clinics and book chapters on various topics in the field of Diabetes. He is currently an Associate Editor of Diabetes Care, and an Editorial Board member of Practical Diabetology, Cardiovascular Diabetology, and Diabetes Management, and is an active reviewer for several journals.

Dr Rosenstock has chaired or been a featured speaker at multiple lectures and presentations about multiple topics on Clinical Diabetes both nationally and internationally.